First‐in‐human, randomized, double‐blind, placebo‐controlled, dose escalation trial of the anti‐herpes simplex virus monoclonal antibody HDIT101 in healthy volunteers

• Váldodahkkit: Antje Blank (Dahkki), Nicolas Hohmann (Dahkki), Marlen Dettmer (Dahkki), Anette Manka‐Stuhlik (Dahkki), Gerd Mikus (Dahkki), Felicitas Stoll (Dahkki), Marlies Stützle‐Schnetz (Dahkki), Daniel Thomas (Dahkki), Evelyn Exner (Dahkki), Beate Schmitt‐Bormann (Dahkki), Torsten Schaller (Dahkki), Rico Laage (Dahkki), Oliver Schönborn‐Kellenberger (Dahkki), Michaela Arndt (Dahkki), Walter E. Haefeli (Dahkki), Jürgen Krauss (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Wiley, 2022-10-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract HDIT101 is a first‐in‐class humanized monoclonal antibody recognizing a conserved epitope in glycoprotein B, a target present on the surface of herpes simplex virus 1 (HSV‐1) and HSV‐2 particles as well as on virus‐infected cells. This was a first‐in‐human, single‐center, double‐blind, plac...